MarketingMedicalPolicy,Access,Value, andEvidenceConsultingData,Technology,and Media
murmuration of birds
Previous
Next

thought leadership

World Orphan Drug Congress 2023: solutions for market access and HEOR

10/12/2023

World Orphan Drug Congress 2023 takes place in Barcelona, from October 31 to November 2. In this policy, access, value, and evidence update, Sanjeev Gogna, Executive Director, shares five access and HEOR challenges for orphan drug manufactures and invites you to meet him at the congress to start discussing solutions. 

Book your meeting with us at World Orphan Drug Congress

from October 31 to November 2

Book now

 

Global payer and policy landscapes are rapidly evolving, so it is important for orphan drug manufacturers to understand the new evidentiary requirements, economic considerations, and service implications related to their assets.

Let’s meet at the World Orphan Drug Congress to talk through some of the latest market access and HEOR challenges and opportunities for orphan drugs, including:

1. Political

  • Policies are more established for regulatory approval than for reimbursement.
  • Current value frameworks may not fully capture the value of treatments.

2. Technological

  • Complex manufacturing and delivery mechanisms may require service redesign.
  • Accurate diagnosis may require access to diagnostic/genetic testing.

3. Clinical

  • High level of clinical uncertainty due to small patient numbers, non-comparative trials, surrogate/novel endpoints, and lack of long-term follow-up.
  • Challenging to accurately model long-term outcomes.

4. Economic

  • High cost due to manufacturing complexity and small patient populations
  • Potential for high up-front costs for once-only curative treatments.
  • Potential for innovative payment models and additional data collection, which may be administratively burdensome.
  • Significant pipeline activity across many indications, with potential for differential value across indications.

5. Social

Greater role for patient advocacy and patient and caregiver perspectives.

 

Let’s meet at World Orphan Drug Congress. We have collaborated with clients on multi-year, multi-project partnerships that led to successful launches of orphan drugs. Now is the perfect time to meet and start creating the connections that make better health happen!

Catherine Kielar

Executive Director and Practice Lead, Global Market Access

avatar for Catherine Kielar - Executive Director and Practice Lead, Global Market Access

 

Creating connections across policy, access, value, and evidence for orphan drugs.

We provide cutting-edge market access and pricing and reimbursement solutions for orphan drugs and regenerative medicines across a range of therapeutic areas and services. Our experts will work with you through the whole process, creating connections from early-stage development to evidence generation, evidence synthesis and communication.

Our experience includes:

  • Mapping and understanding the policy landscape and payer requirements for orphan drugs globally.
  • Developing market access roadmaps.
  • Developing numerous value propositions, GVDs, and objections handlers for products indicated for rare diseases.
  • Facilitating in-depth interviews, panels, advisory boards, and mock HTA meetings with payers.
  • Support for obtaining early scientific advice from HTA agencies.
  • Understanding P&R opportunities and challenges, and innovative pricing strategies.
  • Conducting treatment patterns surveys and Delphi panels to understand treatment use and reach clinical consensus.
  • RWE research and strategy development
  • Early economic modeling and model conceptualization
  • PRO strategy, statistical analysis, and publications.
  • Conducting literature reviews, landscape assessments, and HTA reviews.

Download our case studies: market access and HEOR solutions for orphan drugs.

This collection of case studies illustrates some of the solutions to the market access and HEOR challenges faced by manufactures of orphan drugs.

If you cannot meet us at World Orphan Drug Congress, this download is a great place to find out more about our global experience and best-in-class services.

 

We look forward to meeting you at World Orphan Drug Congress., From conducting 50+ market access and HEOR projects over a 3-year period, to supporting the launch of an injectable gene therapy, to developing an EU market access strategy and roadmap for a gene therapy in hemophilia B, – we are experts in policy, access, value, and evidence for orphan drugs and are excited about meeting you at the congress!

Sanjeev Gogna

Executive Director

avatar for Sanjeev Gogna - Executive Director

 

Thought leadership

How we use cookies

Cookies are files saved on your phone, tablet or computer when you visit a website.

We use cookies to store information about how you use the Fishawack Health website, such as the pages you visit.

For more information, check the cookie statement

32E8261E-A569-4B66-ACC6-3CB772DDEDEE

Cookie settings

We use 4 types of cookies. You can choose which cookies you're happy for us to use.

Cookies that measure website use.

We use Google Analytics to measure how you use the website so we can improve it based on user needs. We do not allow Google to use or share the data about how you use this site.

  • how you got to the site
  • the pages you visit on fishawack.com, and how long you spend on each page
  • what you click on while you're visiting the site

Cookies that help with our communications and marketing

These cookies may be set by third party websites and do things like measure how you view Vimeo videos that are on Fishawack.com.

Cookies that remember your settings

These cookies do things like remember your preferences and the choices you make, to personalize your experience of using the site.

Strictly necessary cookies

These essential cookies do things like remember your progress through a form (eg. Registering for new content alerts).

These cookies always need to be on.